Hanmi Pharm Reflects Upfront Payment from Lilly... Q2 Operating Profit Up 117%

Recognition of SONEFEGLUTIDE Upfront Payment
Sales of 467.2 Billion Won and Operating Profit of 131.1 Billion Won
First-Half Sales Reach 860.2 Billion Won... "Record-Breaking Results Within Reach"

Hanmi Pharm more than doubled its operating profit year-on-year in the second quarter by recognizing the upfront payment from Eli Lilly for the technology transfer of SONEFEGLUTIDE. Prescription growth of flagship products such as Rosuzet and expanded co-sales partnerships with global pharmaceutical companies exceeded market expectations.

On July 28, Hanmi Pharm announced its provisional consolidated earnings for the second quarter of 2026, reporting sales of 467.2 billion won, operating profit of 131.1 billion won, and net profit of 84.1 billion won. Compared to the same period last year, sales increased by 29.3%, with operating profit and net profit up by 116.9% and 95.5%, respectively. The company invested 60.3 billion won in research and development (R&D), which is 12.9% of its sales.

Exterior view of Hanmi Group headquarters. Hanmi Pharm

For the first half of the year, Hanmi Pharm posted cumulative sales of 860.2 billion won, operating profit of 184.7 billion won, and net profit of 135.2 billion won. Compared to the same period last year, these represent increases of 14.4%, 54.6%, and 54.2%, respectively. The company stated that it is likely to achieve its highest annual sales since its establishment yet again this year.

An official from Hanmi Pharm said, "The strong growth of key products such as Rosuzet, increased sales from expanded co-promotion with global pharmaceutical companies, and the upfront payment received from Eli Lilly for the SONEFEGLUTIDE technology transfer all contributed to the solid results this quarter."

No. 1 in Outpatient Prescriptions for 8 Consecutive Years... Rosuzet at 61.6 Billion Won in Q2

Domestic business also bolstered the company’s results. According to UBIST, Hanmi Pharm achieved outpatient prescription sales of 561.6 billion won for the first half, maintaining its position as the top domestic outpatient prescription sales company for eight consecutive years since 2018.

By product, second quarter outpatient prescription sales for Rosuzet, the combination drug for dyslipidemia, rose by 10.1% year-on-year to 61.6 billion won. The antihypertensive product group 'Amozaltan Family' posted sales of 37 billion won, while the gastroesophageal reflux disease product group 'Esomezole Family' recorded 14.6 billion won in sales.

Beijing Hanmi Feels Impact of Centralized Procurement... Hanmi Fine Chemical Operating Profit Up 76.7%

Group subsidiary performances were mixed. The Chinese subsidiary, Beijing Hanmi Pharmaceutical, saw second quarter sales of 60.7 billion won. Due to both the seasonal off-season and the impact of the centralized procurement system in China, both sales and operating profit decreased year-on-year. Beijing Hanmi plans to increase its market share in competitive centralized procurement product groups while also fostering products not subject to centralized procurement and accelerating new drug development to secure new growth drivers.

API (active pharmaceutical ingredient) specialist subsidiary Hanmi Fine Chemical recorded second quarter sales of 24 billion won, up 4.4% year-on-year. With increased API exports to Japan and the expansion of high-margin CDMO (Contract Development and Manufacturing Organization) orders, operating profit soared by 76.7%.

Obesity Pipeline Accelerates... Preparing for Epelfiglenatide Commercialization This Year

In the R&D division, Hanmi Pharm is operating more than 30 innovative pipelines in obesity/metabolism, rare diseases, and oncology. The company is pursuing differentiated strategies by adopting new modalities to enhance global technological competitiveness.

Hanmi Pharm is preparing all necessary steps for the commercialization of its GLP-1 obesity drug, Epelfiglenatide, by the end of the year. The next-generation triple-action obesity therapy (LA-GLP/GIP/GCG, HM15275) and the world’s first muscle-increasing obesity treatment (LA-UCN2, HM17321) are under development, having entered Phase 2 and Phase 1 clinical trials in the United States, respectively.

Hanmi Pharm CEO Hwang Sangyeon said, “Despite the uncertain business environment, we are focusing the organization’s capabilities on innovation to create future growth engines. Through responsible management and continuous innovation, we will enhance corporate value and create a new springboard for the company’s next leap forward.”

This content was produced with the assistance of AI translation services.